{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:02:32Z","timestamp":1783188152595,"version":"3.54.6"},"reference-count":66,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2023-152388OA-I00"],"award-info":[{"award-number":["PID2023-152388OA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008723","name":"Universidad de C\u00e1diz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["EMC21-00041"],"award-info":[{"award-number":["EMC21-00041"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["UCA 2022-2023"],"award-info":[{"award-number":["UCA 2022-2023"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jlr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Lipid Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jlr.2024.100676","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T02:43:05Z","timestamp":1729824185000},"page":"100676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting acetyl-CoA carboxylases for the treatment of MASLD"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0692-4744","authenticated-orcid":false,"given":"Mar\u00eda Antonia","family":"Mateo-Mar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-6434","authenticated-orcid":false,"given":"Michele","family":"Alves-Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlr.2024.100676_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib3","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.cgh.2015.07.029","article-title":"Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes","volume":"13","author":"Ahmed","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD single topic conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.4254\/wjh.v7.i18.2155","article-title":"Advances in hepatocellular carcinoma: nonalcoholic steatohepatitis-related hepatocellular carcinoma","volume":"7","author":"Khan","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib6","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jlr.2024.100676_bib7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.22845","article-title":"Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population","volume":"49","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jlr.2024.100676_bib9","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/j.orcp.2013.08.003","article-title":"Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria","volume":"8","author":"Boyraz","year":"2014","journal-title":"Obes. Res. Clin. Pract."},{"key":"10.1016\/j.jlr.2024.100676_bib10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin. Gastroenterol Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib12","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0000000000000080","article-title":"Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans","volume":"25","author":"Jacome-Sosa","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jlr.2024.100676_bib16","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2024.100676_bib17","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib18","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1016\/j.tjnut.2023.09.018","article-title":"Isotope labeling and biochemical assessment of liver-triacylglycerol in patients with different levels of histologically-graded liver disease","volume":"153","author":"Syed-Abdul","year":"2023","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.jlr.2024.100676_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol. Rev. Camb Philos. Soc."},{"key":"10.1016\/j.jlr.2024.100676_bib20","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1016\/S0021-9258(18)68807-6","article-title":"Regulation of acetyl-coenzyme A carboxylase. I. Purification and properties of two forms of acetyl-coenzyme A carboxylase from rat liver","volume":"263","author":"Thampy","year":"1988","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2024.100676_bib21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1042\/bst0251232","article-title":"Isoforms of acetyl-CoA carboxylase: structures, regulatory properties and metabolic functions","volume":"25","author":"Brownsey","year":"1997","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jlr.2024.100676_bib22","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1126\/science.1056843","article-title":"Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2","volume":"291","author":"Abu-Elheiga","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jlr.2024.100676_bib23","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1073\/pnas.0603115103","article-title":"Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis","volume":"103","author":"Mao","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2024.100676_bib24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1172\/JCI27300","article-title":"Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2","volume":"116","author":"Savage","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1073\/pnas.97.4.1444","article-title":"The subcellular localization of acetyl-CoA carboxylase 2","volume":"97","author":"Abu-Elheiga","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl","key":"10.1016\/j.jlr.2024.100676_bib26","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1194\/jlr.R800079-JLR200","article-title":"Fatty acid metabolism: target for metabolic syndrome","volume":"50","author":"Wakil","year":"2009","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100676_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1160440","article-title":"Mitochondrial CPT1A: insights into structure, function, and basis for drug development","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jlr.2024.100676_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/13543784.2019.1657825","article-title":"Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1\/2 inhibitors","volume":"28","author":"Chen","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jlr.2024.100676_bib29","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 Weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jhep.2023.10.042","article-title":"Pharmacologic inhibition of lipogenesis for the treatment of NAFLD","volume":"80","author":"Esler","year":"2024","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib31","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.jlr.2024.100676_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.jlr.2024.100676_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.nutr.27.061406.093618","article-title":"ChREBP, a transcriptional regulator of glucose and lipid metabolism","volume":"27","author":"Postic","year":"2007","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.jlr.2024.100676_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tem.2013.01.003","article-title":"Novel insights into ChREBP regulation and function","volume":"24","author":"Filhoulaud","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jlr.2024.100676_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2018","journal-title":"Compr. Physiol."},{"issue":"Suppl 2","key":"10.1016\/j.jlr.2024.100676_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2010.01275.x","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c","volume":"12","author":"Ferr\u00e9","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jlr.2024.100676_bib37","first-page":"351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.jlr.2024.100676_bib38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1872-034X.2008.00464.x","article-title":"Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease","volume":"39","author":"Mitsuyoshi","year":"2009","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.jlr.2024.100676_bib39","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1172\/JCI118645","article-title":"Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet","volume":"97","author":"Hudgins","year":"1996","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jhep.2021.02.027","article-title":"Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial","volume":"75","author":"Geidl-Flueck","year":"2021","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150996","article-title":"Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease","volume":"131","author":"Cohen","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1039\/C1FO10111K","article-title":"Fructose containing sugars modulate mRNA of lipogenic genes ACC and FAS and protein levels of transcription factors ChREBP and SREBP1c with no effect on body weight or liver fat","volume":"3","author":"Janevski","year":"2012","journal-title":"Food Funct."},{"key":"10.1016\/j.jlr.2024.100676_bib43","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI81993","article-title":"ChREBP regulates fructose-induced glucose production independently of insulin signaling","volume":"126","author":"Kim","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jlr.2024.100676_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jlr.2024.100676_bib45","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.30097","article-title":"Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents","volume":"68","author":"Goedeke","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jlr.2024.100676_bib46","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1021\/jm5016022","article-title":"Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes","volume":"57","author":"Griffith","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jlr.2024.100676_bib47","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s42255-020-00272-9","article-title":"De novo lipogenesis is essential for platelet production in humans","volume":"2","author":"Kelly","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jlr.2024.100676_bib48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.jlr.2024.100676_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/13543784.2020.1668374","article-title":"GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jlr.2024.100676_bib50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/00498254.2022.2062487","article-title":"Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans","volume":"52","author":"Ryder","year":"2022","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jlr.2024.100676_bib51","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jlr.2024.100676_bib52","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jlr.2024.100676_bib53","doi-asserted-by":"crossref","first-page":"27299","DOI":"10.1074\/jbc.M113.485219","article-title":"Glycerol-3-phosphate acyltransferase (GPAT)-1, but not GPAT4, incorporates newly synthesized fatty acids into triacylglycerol and diminishes fatty acid oxidation","volume":"288","author":"Wendel","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jlr.2024.100676_bib54","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","article-title":"PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein","volume":"15","author":"Johnson","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jlr.2024.100676_bib55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: potential therapeutic implications of pharmacology","volume":"45","author":"Amin","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jlr.2024.100676_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","article-title":"Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor\/firsocostat","volume":"21","author":"Lawitz","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jlr.2024.100676_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100339","article-title":"Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate","volume":"64","author":"Dandan","year":"2023","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jlr.2024.100676_bib58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1586\/14779072.6.10.1319","article-title":"Fenofibrate: treatment of hyperlipidemia and beyond","volume":"6","author":"Rosenson","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.jlr.2024.100676_bib59","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1073\/pnas.0505714102","article-title":"Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal","volume":"102","author":"Abu-Elheiga","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2024.100676_bib60","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/MCB.01122-06","article-title":"Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice","volume":"27","author":"Harada","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jlr.2024.100676_bib61","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1073\/pnas.0913492107","article-title":"Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake","volume":"107","author":"Olson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2024.100676_bib62","doi-asserted-by":"crossref","first-page":"10207","DOI":"10.1073\/pnas.1733877100","article-title":"Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat\/high-carbohydrate diets","volume":"100","author":"Abu-Elheiga","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2024.100676_bib63","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1073\/pnas.0706794104","article-title":"Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity","volume":"104","author":"Choi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jlr.2024.100676_bib64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/jpet.121.000786","article-title":"Selective acetyl-CoA carboxylase 1 inhibitor improves hepatic steatosis and hepatic fibrosis in a preclinical nonalcoholic steatohepatitis model","volume":"379","author":"Tamura","year":"2021","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jlr.2024.100676_bib65","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s00125-012-2554-9","article-title":"Inhibition of acetyl-CoA carboxylase 2 enhances skeletal muscle fatty acid oxidation and improves whole-body glucose homeostasis in db\/db mice","volume":"55","author":"Glund","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jlr.2024.100676_bib66","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/jpet.119.263590","article-title":"A\u00a0novel acetyl-CoA carboxylase 2 selective inhibitor improves whole-body insulin resistance and hyperglycemia in diabetic mice through target-dependent pathways","volume":"372","author":"Takagi","year":"2020","journal-title":"J.\u00a0Pharmacol. Exp. Ther."}],"container-title":["Journal of Lipid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227524001810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022227524001810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:11:25Z","timestamp":1777417885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022227524001810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0022227524001810"],"URL":"https:\/\/doi.org\/10.1016\/j.jlr.2024.100676","relation":{},"ISSN":["0022-2275"],"issn-type":[{"value":"0022-2275","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","name":"articletitle","label":"Article Title"},{"value":"Journal of Lipid Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlr.2024.100676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100676"}}